News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
719,651 Results
Type
Article (40784)
Company Profile (268)
Press Release (678591)
Multimedia
Podcasts (78)
Webinars (17)
Section
Business (204618)
Career Advice (2020)
Deals (35524)
Drug Delivery (105)
Drug Development (81342)
Employer Resources (173)
FDA (16386)
Job Trends (14934)
News (346256)
Policy (32708)
Tag
Academia (2558)
Accelerated approval (30)
Adcomms (24)
Allergies (130)
Alliances (49576)
ALS (166)
Alzheimer's disease (1643)
Antibody-drug conjugate (ADC) (291)
Approvals (16626)
Artificial intelligence (482)
Autoimmune disease (133)
Automation (34)
Bankruptcy (361)
Best Places to Work (11637)
BIOSECURE Act (20)
Biosimilars (181)
Biotechnology (174)
Bladder cancer (152)
Brain cancer (54)
Breast cancer (607)
Cancer (4592)
Cardiovascular disease (381)
Career advice (1702)
Career pathing (34)
CAR-T (269)
CDC (44)
Celiac Disease (1)
Cell therapy (706)
Cervical cancer (35)
Clinical research (69290)
Collaboration (1586)
Company closure (4)
Compensation (1085)
Complete response letters (50)
COVID-19 (2701)
CRISPR (84)
C-suite (757)
Cystic fibrosis (142)
Data (5954)
Decentralized trials (2)
Denatured (25)
Depression (123)
Diabetes (483)
Diagnostics (6634)
Digital health (40)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (233)
Drug pricing (177)
Drug shortages (28)
Duchenne muscular dystrophy (217)
Earnings (89853)
Editorial (51)
Employer branding (21)
Employer resources (151)
Events (116935)
Executive appointments (949)
FDA (19311)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (23)
Funding (1407)
Gene editing (186)
Generative AI (40)
Gene therapy (566)
GLP-1 (935)
Government (4635)
Grass and pollen (6)
Guidances (378)
Healthcare (18859)
HIV (53)
Huntington's disease (42)
IgA nephropathy (81)
Immunology and inflammation (237)
Immuno-oncology (45)
Indications (83)
Infectious disease (2953)
Inflammatory bowel disease (183)
Inflation Reduction Act (14)
Influenza (107)
Intellectual property (229)
Interviews (315)
IPO (16630)
IRA (49)
Job creations (3640)
Job search strategy (1427)
Kidney cancer (15)
Labor market (80)
Layoffs (543)
Leadership (29)
Legal (7945)
Liver cancer (90)
Longevity (12)
Lung cancer (628)
Lymphoma (357)
Machine learning (40)
Management (59)
Manufacturing (730)
MASH (157)
Medical device (13711)
Medtech (13752)
Mergers & acquisitions (19906)
Metabolic disorders (1201)
Multiple sclerosis (147)
NASH (16)
Neurodegenerative disease (293)
Neuropsychiatric disorders (76)
Neuroscience (2795)
NextGen: Class of 2026 (6520)
Non-profit (4505)
Now hiring (62)
Obesity (557)
Opinion (251)
Ovarian cancer (158)
Pain (179)
Pancreatic cancer (214)
Parkinson's disease (266)
Partnered (32)
Patents (463)
Patient recruitment (434)
Peanut (55)
People (58678)
Pharmaceutical (63)
Pharmacy benefit managers (27)
Phase I (21612)
Phase II (30488)
Phase III (22734)
Pipeline (4516)
Policy (267)
Postmarket research (2564)
Preclinical (9178)
Press Release (64)
Prostate cancer (222)
Psychedelics (43)
Radiopharmaceuticals (272)
Rare diseases (760)
Real estate (5949)
Recruiting (69)
Regulatory (24189)
Reports (51)
Research institute (2377)
Resumes & cover letters (351)
Rett syndrome (26)
RNA editing (15)
RSV (74)
Schizophrenia (143)
Series A (230)
Series B (181)
Service/supplier (11)
Sickle cell disease (94)
Special edition (21)
Spinal muscular atrophy (154)
Sponsored (40)
Startups (3613)
State (2)
Stomach cancer (17)
Supply chain (101)
Tariffs (81)
The Weekly (51)
Vaccines (963)
Venture capital (84)
Weight loss (359)
Women's health (80)
Worklife (17)
Date
Today (58)
Last 7 days (640)
Last 30 days (1994)
Last 365 days (30140)
2026 (1367)
2025 (30169)
2024 (35216)
2023 (40076)
2022 (51174)
2021 (55711)
2020 (54085)
2019 (46539)
2018 (35018)
2017 (32110)
2016 (31481)
2015 (37552)
2014 (31321)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (736)
Alabama (78)
Alaska (7)
Arizona (300)
Arkansas (13)
Asia (39083)
Australia (6376)
California (10830)
Canada (3167)
China (1032)
Colorado (453)
Connecticut (456)
Delaware (322)
Europe (84197)
Florida (1604)
Georgia (343)
Hawaii (2)
Idaho (61)
Illinois (821)
India (57)
Indiana (500)
Iowa (21)
Japan (394)
Kansas (124)
Kentucky (37)
Louisiana (25)
Maine (71)
Maryland (1346)
Massachusetts (7803)
Michigan (307)
Minnesota (603)
Mississippi (5)
Missouri (123)
Montana (31)
Nebraska (27)
Nevada (116)
New Hampshire (77)
New Jersey (2901)
New Mexico (28)
New York (2868)
North Carolina (1399)
North Dakota (8)
Northern California (5250)
Ohio (319)
Oklahoma (20)
Oregon (40)
Pennsylvania (2197)
Puerto Rico (19)
Rhode Island (46)
South America (1101)
South Carolina (60)
South Dakota (1)
Southern California (4201)
Tennessee (168)
Texas (1672)
United States (38519)
Utah (321)
Vermont (1)
Virginia (248)
Washington D.C. (78)
Washington State (881)
West Virginia (4)
Wisconsin (97)
Wyoming (2)
719,651 Results for "cytokinetics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cardiovascular disease
Cytokinetics’ Moment of Truth: Can Aficamten Take On BMS in Hypertrophic Cardiomyopathy?
After 27 years in business, Cytokinetics hopes to pit its own cardiac myosin inhibitor against one it initially developed—now owned by Bristol Myers Squibb—in a market worth billions. Aficamten has a PDUFA date of Dec. 26.
December 19, 2025
·
5 min read
·
Dan Samorodnitsky
Press Releases
Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
·
3 min read
Cardiovascular disease
Cytokinetics Soars on Aficamten’s ‘Best-in-Class’ Performance in Phase III Cardio Study
Data from the late-stage MAPLE-HCM study position Cytokinetics’ cardiac myosin inhibitor aficamten as a potential first-line therapy for patients with obstructive hypertrophic cardiomyopathy.
September 3, 2025
·
2 min read
·
Tristan Manalac
Approvals
Cytokinetics Wins FDA Approval, Clearing Way to Challenge BMS in Heart Disease Market
Stifel analysts said the label for cardiac myosin inhibitor Myqorzo is in line with their expectations and is differentiated compared with BMS’ Camzyos.
December 22, 2025
·
2 min read
·
Nick Paul Taylor
Press Releases
Cytokinetics to Participate in November 2025 Investor Conferences
November 4, 2025
·
3 min read
Press Releases
Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy
December 17, 2025
·
8 min read
Press Releases
Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy
December 15, 2025
·
9 min read
Press Releases
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - December 16, 2025
December 17, 2025
·
4 min read
Press Releases
Cytokinetics to Announce Third Quarter Results on November 5, 2025
October 22, 2025
·
3 min read
Press Releases
Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
December 22, 2025
·
14 min read
1 of 71,966
Next
